Publications

Detailed Information

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status

Cited 10 time in Web of Science Cited 12 time in Scopus
Authors

Babapour Mofrad, Rosha; Scheltens, Philip; Kim, SangYun; Kang, Sungmin; Youn, Young Chul; An, Seong Soo. A.; Tomassen, Jori; van Berckel, Bart N. M.; Visser, Pieter J.; van der Flier, Wiesje M.; Teunissen, Charlotte E.

Issue Date
2021-07-26
Publisher
BMC
Citation
Alzheimer's Research & Therapy. 2021 Jul 26;13(1):133
Keywords
Blood-based biomarkerPlasma Aβ oligomerAmyloid statusMultimer detection systemLong-term storage
Abstract
Objective
We assessed the performance of plasma amyloid oligomerization tendency (OAβ) as a marker for abnormal amyloid status. Additionally, we examined long-term storage effects on plasma OAβ.

Methods
We included 399 subjects regardless of clinical diagnosis from the Amsterdam Dementia Cohort and European Medical Information Framework for AD project (age, 63.8 ± 6.6; 44% female). Amyloid status was determined by visual read on positron emission tomography (PET; nabnormal = 206). Plasma OAβ was measured using the multimer detection system (MDS). Long-term storage effects on MDS-OAβ were assessed using general linear models. Associations between plasma MDS-OAβ and Aβ-PET status were assessed using logistic regression and receiver operating characteristics analyses. Correlations between plasma MDS-OAβ and CSF biomarker levels were evaluated using Pearson correlation analyses.

Results
MDS-OAβ was higher in individuals with abnormal amyloid, and it identified abnormal Aβ-PET with an area under the curve (AUC) of 0.74 (95% CI, 0.67–0.81), especially in samples with a storage duration < 4 years. Combining APOEe4 and age with plasma MDS-OAβ revealed an AUC of 81% for abnormal amyloid PET status (95% CI, 74–87%). Plasma MDS-OAβ correlated negatively with MMSE (r = − 0.29, p < .01) and CSF Aβ42 (r = − 0.20, p < 0.05) and positively with CSF Tau (r = 0.20, p = 0.01).

Conclusions
Plasma MDS-OAβ combined with APOEe4 and age accurately identifies brain amyloidosis in a large Aβ-confirmed population. Using plasma MDS-OAβ as a screener reduced the costs and number of PET scans needed to screen for amyloidosis, which is relevant for clinical trials. Additionally, plasma MDS-OAβ levels appeared affected by long-term storage duration, which could be of interest for others measuring plasma Aβ biomarkers.
ISSN
1758-9193
Language
English
URI
https://hdl.handle.net/10371/174829
DOI
https://doi.org/10.1186/s13195-021-00873-w
Files in This Item:
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share